3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
2
Unknown
1
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
8
Gastrointestinal
6
Thoracic
3
Gynecologic
3
Endocrine
3
CNS
3
Sarcoma
2
Other solid neoplasm
2
Other hematologic neoplasm
2
Head & Neck
2
Plasma cell
1
Lymphoid
1
Genitourinary
1
Classical hematology
1
Conditions
Stomatitis
1
Multiple Myeloma
1
Lymphoma
1
Hematologic Neoplasms
1
Interventions
Dexamethasone
70
Cyclophosphamide
44
Bortezomib
41
Lenalidomide
25
Melphalan
24
Thalidomide
19
pomalidomide
17
daratumumab
14
fludarabine
13
carfilzomib
10
Filgrastim
8
Doxorubicin
8
Busulfan
6
isatuximab
5
Prednisone
5
Peripheral Blood Stem Cell Transplantation
5
Calcium Dobesilate
5
Bendamustine Hydrochloride
5
selinexor
4
sargramostim
4
fludarabine phosphate
4
Surveys and Questionnaires
4
Etoposide
4
Clarithromycin
4
liposomal doxorubicin
3
ixazomib
3
dexamethasone acetate
3
Radiotherapy
3
Neoadjuvant Therapy
3
Mycophenolic Acid
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Saline Solution
×
Plasma cell
×
Clear all
NCT05493800
2024-05-29
Capella
MitoImmune Therapeutics
Phase 2
Unknown
60 enrolled